ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces the success of its capital increase with preferential subscription rights (the “Rights Issue”), launched on May 27, 2026, which has been subscribed at 100% after partial allocation of the guarantee commitments. The Company also announces the submission of the drawdown notice for the first tranche of non-convertible bonds (the “Bonds Financing” and, together with the Rights Issue, the “Transaction”) by Fenja Capital II A/S (“Fenja Capital”), an independent asset manager based in Denmark focused on investing in innovative companies in healthcare, biotech, and technology.
Cyrille Tupin, CEO of Abionyx Pharma, said:
“The successful completion of this Rights Issue, together with the bonds financing provided by Fenja Capital, represents a major milestone for ABIONYX Pharma. I would like to sincerely thank our existing shareholders for their continued loyalty, welcome our new investors, and express our gratitude to Fenja Capital for its confidence and commitment to our Company. We are particularly pleased to welcome the support of Fenja Capital as a financing partner in supporting this Rights Issue and in its first financing transaction in the French market.
